Journal
CIRCULATION
Volume 138, Issue 23, Pages E740-E749Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIR.0000000000000613
Keywords
AHA Scientific Statements; advanced cardiac life support; adult; anti-arrhythmia agents; cardiopulmonary resuscitation; heart arrest; tachycardia; ventricular; ventricular fibrillation
Funding
- NHLBI NIH HHS [K23 HL128814, R01 HL123980] Funding Source: Medline
Ask authors/readers for more resources
Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available